MaxCyte (MXCT) investor relations material

Executive summary

• Q2 2026 revenue was $7.3 million, with $6.5 million core revenue and $0.8 million SPL program-related revenue, exceeding expectations despite inventory drawdown and discontinued partner programs; first half 2026 revenue was $16.9 million, down 10% year-over-year, with a net loss of $13.6 million and an accumulated deficit of $275.1 million as of June 30, 2026.

• Sequential Q2 growth was driven by instrument placements, especially the GTx platform, and ongoing program advancement, while the ExPERT DTx platform launched in February 2026 targeting high-throughput research.

• A significant multi-platform technology license partnership was signed with Genentech post-quarter, expanding platform reach and validating technology strength.

• The company maintains 30 licensed partnerships, including 29 SPL partners and the new Genentech agreement, with five partner programs potentially launching commercially in the next two years.

• Operating expenses decreased significantly due to restructuring and cost controls, reflecting workforce reductions and lower stock-based compensation, marketing, and professional fees.

Financial highlights

• Q2 2026 total revenue was $7.3 million, down 15% year-over-year from $8.5 million in Q2 2025, mainly due to a 21% drop in core revenue.

• Instrument revenue was $1.8 million (vs. $2.1 million prior year), license revenue $1.8 million (vs. $2.6 million), and processing assembly revenue $2.3 million (vs. $3.1 million); SPL program-related revenue rose to $0.8 million from $0.3 million year-over-year, driven by increased CASGEVY royalties.

• Gross margin was 77% (vs. 82% prior year); non-GAAP adjusted gross margin was 77% (vs. 83%).

• Net loss improved to $8.9 million from $12.4 million in Q2 2025; EBITDA loss was $9.3 million versus $13.1 million year-over-year.

• Cash, cash equivalents, and investments totaled $141.9 million at quarter-end; no debt.

Outlook and guidance

• 2026 revenue guidance reiterated at $30–32 million, with $25–27 million core revenue and $5 million SPL milestones/royalties; SPL revenue guidance includes ~$3 million from milestones and ~$2 million from commercial royalties.

• Low single-digit year-over-year revenue growth expected in the second half, with Q4 slightly higher than Q3 due to seasonality.

• Anticipates ending 2026 with at least $130.5 million in cash and investments, excluding further share repurchases.

• Management expects total revenue to increase over time as customer programs advance and the installed base under SPL agreements grows, but anticipates continued variability in SPL milestone and royalty revenue.

• The company plans to continue investing in R&D and commercial expansion, expecting near-term operating losses.